Beximco PharmaceuticalsLSE:BXP 67 Median PS Value is £0.77 as of Jul. 02, 2026, which is 100% below its 10-year median of 0.70. GuruFocus rates LSE:BXP with a GF Score™ of 67/100 and a GF Value™ of £0.45 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 545 Drug Manufacturers companies, Beximco Pharmaceuticals ranks better than 69.91% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Beximco Pharmaceuticals's Median PS Value or its related term are showing as below:
LSE:BXP'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.35 Med: 0.7 Max: 1.69
Current: 0.65
During the past 13 years, the highest Price to Median PS Value of Beximco Pharmaceuticals was 1.69. The lowest was 0.35. And the median was 0.70.
LSE:BXP's Price-to-Median-PS-Value is ranked better than 69.91% of 545
companies
in the Drug Manufacturers industry
Industry Median: 0.85
vs LSE:BXP: 0.65
Beximco Pharmaceuticals (LSE:BXP) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Beximco Pharmaceuticals's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.50
/
0.77
=
0.65
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beximco Pharmaceuticals Median PS Value Related Terms
Beximco Pharmaceuticals Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Beximco Pharmaceuticals's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beximco Pharmaceuticals Price-to-Median-PS-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beximco Pharmaceuticals's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Beximco Pharmaceuticals's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 1.0591.
Beximco Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was £0.727.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beximco Pharmaceuticals (LSE:BXP) has a Median PS Value of £0.77 as of Jul. 02, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Beximco Pharmaceuticals and its competitors. This is 10% above median its historical median of 0.70. Over the past decade, Beximco Pharmaceuticals' Median PS Value has ranged from 0.35 to 1.69. According to the industry distribution chart, Beximco Pharmaceuticals ranks #164 out of 545 companies in the Drug Manufacturers industry, placing it in the top 30.1%.
Is Beximco Pharmaceuticals' Median PS Value too high?
Beximco Pharmaceuticals' current Median PS Value of £0.77 is 10% above median its 10-year median of 0.70. Over the past 10 years, this metric has ranged from a low of 0.35 to a high of 1.69. Based on the distribution chart, Beximco Pharmaceuticals ranks #164 out of 545 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Beximco Pharmaceuticals has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beximco Pharmaceuticals' Median PS Value compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Beximco Pharmaceuticals ranks #164 out of 545 companies for Median PS Value. This puts Beximco Pharmaceuticals in the upper half of its industry. The industry median Median PS Value is 0.85. Historically, Beximco Pharmaceuticals' own Median PS Value has ranged from 0.35 to 1.69 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Drug Manufacturers company?
The median Median PS Value among Drug Manufacturers companies is 0.85, based on 545 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Beximco Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Median PS Value is 0.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beximco Pharmaceuticals's current Median PS Value is £0.77, which is 10% above median its own 10-year median of 0.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beximco Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Beximco Pharmaceuticals (LSE:BXP) is currently considered Modestly Overvalued. The stock's GF Value™ is £0.45, compared to a current price of £0.50 — trading 11.1% above its estimated fair value. The current Median PS Value is £0.77, which is 10% above median its 10-year median of 0.70. Beximco Pharmaceuticals' overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Beximco Pharmaceuticals (LSE:BXP), the current Median PS Value is £0.77 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beximco Pharmaceuticals (LSE:BXP) Overvalued in 2026?
Based on GuruFocus' analysis, Beximco Pharmaceuticals stock appears to be overvalued.
The current stock price of £0.50 is trading 11.1% above its estimated GF Value™ of £0.45.
GuruFocus considers Beximco Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for LSE:BXP:
Median PS Value: £0.77 (10% above median its 10-year median of 0.70)
GF Value™: £0.45 vs. price of £0.50 (11.1% above fair value)
No single metric tells the full story. See the LSE:BXP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beximco Pharmaceuticals PLC is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.
67GF Score
Get the complete analysis for LSE:BXP
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:BXP has been successfully added to your 
